Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of MitoImmune Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
MitoImmune Therapeutics
korearepublicofnew Flag
Country
Country
South Korea
Address
Address
Gangnam Daero 62, Gil 7, Haeju Building 702, Seoul
Telephone
Telephone
02-6933-6725
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

MIT-001 is an anti-inflammatory and anti-necrotic agent, specifically scavenging ROS in the mitochondria. MitoImmune plans to initiates a Phase 2 trial of oral mucositis (OM) prevention and is expanding OM treatment into hematopoietic stem cell transplantation.


Lead Product(s): MIT-001

Therapeutic Area: Gastroenterology Product Name: MIT-001

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY